Transplant’s NBC debut wins its timeslot

The Canadian medical procedural was the most-watched series in its 10 p.m. timeslot on Monday for its U.S. broadcast debut on NBC.

Transplant has started off strong in its U.S. broadcast debut on NBC.

The Sphère Média Plus-produced medical procedural won its 10 p.m. timeslot on Monday (Sept. 1) with an estimated 4 million viewers. The series was second in overall audience only to its lead-in America’s Got Talent, which raked in more than 6 million viewers. Transplant scored a 0.4 in the 18 to 49 demo, with the Denver Nuggets vs. Utah Jazz NBA playoff game winning the demo with a 1.0.

NBC picked up Transplant in May and announced it would be part of its fall lineup last month, a rarity for a Canadian acquisition on a U.S. network. Episodes will be available to stream in the U.S. on the newly-launched SVOD Peacock, which also acquired the upcoming Global drama and Canada/U.K. copro Departure, set to debut on the streamer on Sept. 17.

Transplant, created by showrunner and executive producer Joseph Kay, became a winning series for CTV when it debuted in February. The series premiere brought in an average audience of 1.3 million, and it peaked at 1.7 million for the season one finale. A second season was announced at CTV’s digital upfront presentation in June.

Executive producers on Transplant include Bruno Dubé, Virginia Rankin, Tara Woodbury, Jeremy Spry and Jocelyn Deschênes. Holly Dale, who directed the pilot, serves as co-executive producer. NBCUniversal International Global Distribution handles worldwide sales for the series.